Tear Trough Filler

The tear trough is one of the easiest areas of the face to over-treat because several very different under-eye problems can cast a similar shadow. A patient may point beneath the eye and describe tiredness, darkness, hollowing or ageing as though these were interchangeable diagnoses. They are not. A true infraorbital hollow can create a shadow that responds well to carefully selected volume replacement, but pigmentation, thin translucent skin, visible vessels, lower-eyelid fat prolapse, malar edema and skin laxity can produce a similar complaint without being filler problems.

This is why I do not begin an under-eye consultation by deciding where filler should go. I begin by deciding what is actually creating the darkness or depression. Sometimes the most useful treatment is a small amount of hyaluronic acid placed in the correct anatomical context. Sometimes improving midface support reduces the hollow enough that direct tear-trough filler becomes unnecessary. In another patient, additional material beneath the eye would make an already puffy region heavier. The label “tear trough” describes a visible transition; it does not tell me that filling that transition is the correct solution.

The tear trough is an anatomical transition, not simply an empty groove

The lower eyelid does not end abruptly and the cheek does not begin as a separate object. They meet through a complex transition shaped by the orbital rim, retaining ligaments, orbicularis muscle, superficial and deep fat compartments, skin thickness and the projection of the midface beneath them. The depression we call the tear trough is partly created by the relationship between these structures rather than by a literal empty space that needs to be filled.

This distinction becomes increasingly important with age. The cheek can lose projection, the lid–cheek junction can lengthen, orbital fat may become more visible and the overlying skin can become thinner. A patient can therefore develop a deeper-looking under-eye groove even though the local tear trough is only one component of the change. If the cheek beneath the eye has lost support, placing more and more filler directly into the hollow can camouflage the transition temporarily while leaving the larger anatomical problem untouched.

I prefer to look at the entire lid–cheek relationship before isolating one line. In some patients, restoring a modest amount of midface support softens the tear trough indirectly and allows the under-eye itself to remain almost untreated. That can be a better aesthetic result because the lower eyelid is thin, mobile and unforgiving of unnecessary volume.

“Dark circles” should be separated from true volume loss before filler is considered

Under-eye darkness can arise from several mechanisms. A hollow creates a structural shadow; brown or grey pigmentation changes the colour of the skin itself; thin skin can allow underlying muscle and vessels to show through; edema can create a darker transition by altering the contour around it. Many patients have two or three of these mechanisms simultaneously. This is why a photograph taken under one overhead light can make an under-eye appear dramatically darker while the same face looks very different in diffuse daylight.

Filler is most logical when a significant part of the darkness is created by shadow from a genuine depression. By elevating the depressed transition, the angle at which light reaches the region changes and the dark appearance can improve even though the pigment of the skin has not changed. That is an optical correction produced through anatomy. If the darkness remains equally visible regardless of lighting because pigment itself is dominant, additional volume may do very little.

I want the patient to understand this distinction before treatment, because otherwise a technically excellent filler result can still feel disappointing. The hollow may be corrected while the brown colour remains. The correct conclusion is not necessarily that more filler is required. It may be that filler has already completed the part of the problem that belongs to filler.

The cheek often needs to be assessed before the tear trough itself

Midface support strongly influences the way the lower eyelid transitions into the cheek. When the anterior cheek is relatively flat or has lost deep volume, the lid–cheek junction can appear longer and more hollow. In that anatomy, directly filling the tear trough first can produce a smooth groove sitting above an inadequately supported cheek. The result may look acceptable from the front and less coherent in oblique view.

This is why I often think from below upward. If the cheek is genuinely deficient, a conservative correction there may reduce the apparent trough and change how much direct infraorbital treatment is necessary. The 2025 anatomical review of infraorbital filler treatment follows a similar logic, emphasising assessment and correction of midface volume before direct treatment of the infraorbital hollow in suitable patients. :contentReference[oaicite:1]{index=1}

That does not mean every tear-trough patient should receive cheek filler. A patient with good midface projection and a discrete congenital trough may need no cheek augmentation at all. The point is not to create another automatic treatment. It is to make sure the structure supporting the lower eyelid has been considered before material is placed into one of the thinnest and most visible areas of the face.

Puffiness and hollowing can coexist, which is where filler becomes particularly easy to misuse

A patient can have a depression immediately beneath a lower-eyelid fat pad. Visually, this creates the strange combination of a bag above and a hollow below. Filling the hollow may smooth the transition in selected mild cases, but it does not remove the fat pad. If the protrusion is substantial, raising the tissue underneath it can simply make the entire lower eyelid–cheek region fuller and heavier.

Malar edema and festoons create an even more difficult situation. These patients already have a tendency for fluid or tissue fullness over the upper cheek. Hyaluronic acid attracts and retains water to varying degrees depending on its formulation, and additional material in a region with compromised lymphatic drainage can worsen persistent swelling. This is one of the reasons the under-eye cannot be treated with the same logic as a dry nasolabial fold or a structurally deficient chin.

When bags, festoons or chronic edema dominate, the useful conversation often moves away from “Which filler?” toward whether filler belongs in the area at all. Surgery, treatment of another anatomical layer or simply leaving the region untreated can be more coherent than attempting to hide every contour transition with additional gel.

Thin under-eye skin makes product behaviour visible in a way that other facial regions can tolerate

The lower eyelid provides very little camouflage. A filler that is slightly too superficial, too firm or too hydrophilic can become visible as a ridge, bluish-grey discoloration or persistent fullness. A product that behaves beautifully in a cheek or jawline may therefore be poorly suited to the infraorbital region. Product choice is not simply a question of whether the syringe contains hyaluronic acid.

For this reason, modern infraorbital treatment favours materials with appropriate softness, malleability and relatively limited water attraction. The objective is not to create projection. It is to create a subtle transition that moves naturally with the eyelid and remains inconspicuous beneath thin tissue. A 2025 review specifically emphasised low-hygroscopic, adaptable HA characteristics and conservative volumes for this reason. :contentReference[oaicite:2]{index=2}

The amount required is often smaller than patients expect. That is not undertreatment. In the under-eye, a few tenths of a millilitre can materially alter contour, while an additional fraction can be the difference between a smoother transition and visible fullness. The anatomy rewards restraint much more than the syringe rewards completion.

Persistent swelling is not simply “a little filler that has not settled yet”

Early edema after injection is expected. The tissue has been punctured, manipulated and exposed to a hydrophilic material, so transient swelling does not immediately indicate a complication. The more important question is what happens after the acute inflammatory phase should have resolved. Persistent or recurrent edema can reflect product characteristics, placement, excessive volume, pre-existing malar fluid tendency or interference with local lymphatic drainage.

Late-onset edema is particularly important because it can appear months or even years after injection. A patient may believe the original filler has long since disappeared and not connect new under-eye puffiness with treatment performed several years earlier. Contemporary reviews increasingly recognise this phenomenon and describe both inflammatory and non-inflammatory mechanisms, including disturbed lymphatic and venous flow. :contentReference[oaicite:3]{index=3}

This is why repeated top-ups deserve caution. If the region looks hollow again because surrounding facial volume has changed while residual material remains, adding more HA may worsen a lymphatically sensitive space. The correct response can be reassessment, imaging in selected cases or reduction of old product rather than another syringe.

The blue-grey Tyndall appearance is usually a placement problem, not a new type of dark circle

Hyaluronic acid placed too superficially beneath thin lower-eyelid skin can create a blue-grey hue because of the way light is scattered through the material and overlying tissue. The patient may interpret this as worsening pigmentation, particularly if the original reason for treatment was “dark circles”. The colour can persist as long as the superficial filler remains.

This is one reason I avoid treating darkness without first identifying whether it is shadow or pigment. A patient whose main problem was colour can undergo filler, retain the original pigment and then acquire an additional blue-grey optical effect from superficially placed material. More filler would obviously not solve that sequence.

When HA itself is responsible for an unacceptable contour or discoloration, hyaluronidase provides an important correction option. That reversibility is one of the reasons HA remains the logical filler category around the eye. But the existence of an enzyme does not turn poor indication into good indication. Reversibility is a safety and correction tool, not permission to treat a marginal under-eye simply because we can dissolve it later.

Previous filler changes the consultation even when the patient thinks it has disappeared

Hyaluronic acid can persist in facial tissues longer than the visible aesthetic result suggests. This is particularly relevant around the eyes because relatively small residual amounts can influence contour and fluid behaviour. A patient may return after several years asking to recreate the original result, yet the starting anatomy may still contain product from earlier treatments.

If there is unexplained fullness, nodularity or a history of repeated filler, ultrasound can be useful in selected patients to determine whether material remains and where it sits. I do not think every uncomplicated patient requires imaging, but uncertainty should not be solved by injecting more material into an already uncertain space.

The principle is simple: maintenance is not the same as replacement. We should not assume that because an aesthetic effect has faded, the physical filler volume has disappeared in the same proportion. The under-eye is one of the areas in which cumulative treatment can become visible very slowly and then become difficult to ignore.

The vascular risk is rare, but the consequence changes the threshold for treatment

The infraorbital region contains important arterial connections and sits close to the orbit. As with other facial filler injections, unintended vascular injection can cause skin ischemia; through facial–ophthalmic vascular connections, filler embolisation can in rare cases cause visual compromise. These events are uncommon, but the severity means that the decision to inject should begin before any technical discussion about needle versus cannula.

A 2025 major review of periorbital HA complications documents the common problems—edema, bruising, contour irregularity and blue discoloration—but also includes rare visual loss and orbital filler complications. :contentReference[oaicite:4]{index=4} The point is not to make a common treatment sound frightening. It is to keep the risk–benefit ratio proportional to the aesthetic problem being treated.

If a patient has a barely visible hollow that bothers them only in one lighting condition, my tolerance for procedural risk is different from the patient with a clear anatomical depression that consistently creates a tired appearance. The anatomy does not become safer because the desired change is small. Sometimes the smallness of the desired change is precisely why doing nothing becomes a reasonable option.

There is a point at which lower-eyelid surgery becomes the more anatomically honest treatment

Filler is good at adding support and smoothing selected transitions. It cannot remove redundant skin, reposition substantial prolapsed orbital fat or correct every form of lower-eyelid laxity. When those structural changes dominate, repeated attempts to camouflage them with volume can make the lower face heavier without truly rejuvenating the eye.

Lower blepharoplasty and related surgical approaches can directly address tissues that filler can only disguise. That does not mean surgery is automatically better; it means it belongs to a different problem scale. A patient with a mild congenital tear trough may have no reason to undergo surgery. A patient with significant bags, laxity and festoons may have little reason to keep escalating filler.

I prefer to make that distinction early because it protects the patient from treatment drift. A minimally invasive procedure is not necessarily conservative if it has to be repeated and enlarged in order to chase an anatomical result it was never designed to produce.

The result should be judged after swelling has settled and in more than one lighting condition

Immediately after filler, edema can partially erase the hollow and make the result look unusually smooth. That early appearance can be attractive but misleading. As swelling resolves, the actual contribution of the filler becomes clearer. This is why small early residual asymmetries should not automatically trigger more product at the first opportunity.

I also judge the under-eye in different lighting. A tear trough is fundamentally a three-dimensional contour, and shadows change with the direction of light. If the region looks natural in diffuse daylight, oblique light and facial movement, I am much more interested in that result than in making one studio photograph perfectly shadow-free.

Normal anatomy should remain visible to some degree. There is a natural transition between eyelid and cheek in every adult face. Trying to eliminate it completely often requires exactly the amount of filler that makes the area look puffy. The endpoint is a softer transition, not an anatomically blank under-eye.

Maintenance should begin by asking whether the same hollow still exists

The face changes over time. Midface volume, skin quality, orbital fat and previous filler all change at different rates. A patient who benefited from direct tear-trough filler several years ago may return with a different dominant problem. The new issue may be cheek volume loss, lower-eyelid bags, skin laxity or residual filler rather than recurrence of the original hollow.

This is why I do not think of tear-trough filler as something that must be replaced on a fixed annual schedule. If a useful correction remains, another treatment can create accumulation rather than maintenance. If the anatomy has progressed beyond what filler can treat elegantly, repeating the old solution can become progressively less appropriate even though it once worked very well.

A good maintenance consultation therefore resembles a first consultation. The treatment history matters, but it does not decide the next treatment. The current anatomy does.

What a good tear-trough filler result means to me

I want the lower eyelid to transition into the cheek more smoothly without looking filled. The patient may appear less tired because a structural shadow has softened, but the eye itself should retain its natural shape and the region should remain light rather than heavy. I do not aim to erase every line beneath the eye, and I do not use additional volume to chase pigmentation, bags or fluid retention that filler cannot correct.

The best result is often difficult to identify as an injectable result. There is no shelf of product beneath the eyelid, no blue-grey ridge and no puffiness that appears every morning. The improvement comes from restoring a missing transition rather than adding a new feature to the face.

That is also why some patients are excellent candidates for very little treatment and others are better candidates for none. The under-eye rewards correct indication more than aggressive technique. If the hollow is not genuinely a volume problem, the correct filler volume may be zero.

Frequently asked questions

What is tear-trough filler?

Tear-trough filler usually refers to hyaluronic-acid filler used to soften a true infraorbital hollow and improve the transition between the lower eyelid and cheek. The treatment is most appropriate when structural depression and shadow are meaningful parts of the patient’s concern rather than when pigmentation or eyelid bags are dominant.

Can tear-trough filler remove dark circles?

It can improve darkness caused by shadow from a hollow. It does not directly remove brown pigmentation, visible vessels or other colour changes in the skin, so some patients require another treatment or no filler at all.

Why might the cheek be treated before the under-eye?

Loss of midface support can exaggerate the lid–cheek junction. In suitable patients, restoring that support can soften the tear trough indirectly and reduce the amount of filler required directly beneath the eye.

Can tear-trough filler treat eye bags?

It can occasionally camouflage a mild transition beneath a small fat pad, but it does not remove prolapsed orbital fat. Significant bags, festoons or laxity often require a different treatment strategy.

Why can under-eye filler cause swelling?

The area has delicate lymphatic drainage and very thin tissue. Product properties, injection plane, excessive volume and individual predisposition can all contribute to persistent or delayed edema.

What is the Tyndall effect?

It is a blue-grey appearance that can occur when hyaluronic-acid filler sits too superficially beneath thin skin. When HA is responsible, hyaluronidase can often be used to reduce the material.

Can old under-eye filler still be present years later?

Yes. HA can persist longer than the visible cosmetic effect suggests, and residual product may contribute to fullness or late edema. Reassessment is therefore important before repeated top-ups.

Is tear-trough filler dangerous?

Most adverse effects are minor, such as swelling, bruising or contour irregularity, but rare vascular complications including visual loss have been reported with periocular filler. This is one reason patient selection and anatomical expertise are particularly important.

Can tear-trough filler be dissolved?

Hyaluronic-acid filler can generally be reduced with hyaluronidase when inappropriate volume, edema, superficial product or another HA-related problem requires correction. Dissolving is useful but should not be treated as a substitute for correct initial indication.

When is lower blepharoplasty more appropriate?

Surgical assessment becomes more relevant when significant lower-eyelid fat prolapse, skin excess, festoons or other structural changes dominate the appearance and would require repeated filler simply to camouflage them.

How much filler is needed?

The under-eye usually requires conservative quantities because very small changes are visible beneath thin tissue. The correct amount follows anatomy and may be substantially less than one syringe, particularly after the midface has been assessed.

How often should tear-trough filler be repeated?

There is no fixed maintenance interval. Residual filler can persist and facial anatomy changes with time, so the region should be reassessed before additional treatment rather than automatically refilled according to a calendar.

When would you recommend no tear-trough filler?

I would avoid or redirect treatment when pigmentation, edema, prominent lower-eyelid bags, festoons or skin laxity are the dominant problems, when significant old product remains or when the potential improvement is too small to justify treatment in a high-consequence anatomical region.